S&P 500   4,240.27 (+0.26%)
DOW   32,992.06 (-0.03%)
QQQ   356.81 (+0.53%)
AAPL   172.20 (-0.12%)
MSFT   316.44 (+0.97%)
META   300.48 (-0.15%)
GOOGL   133.54 (+0.84%)
AMZN   126.27 (+1.24%)
TSLA   249.85 (+1.35%)
NVDA   436.99 (+0.42%)
NIO   8.56 (-0.58%)
BABA   84.54 (+0.00%)
AMD   100.76 (+0.68%)
T   14.70 (-0.54%)
F   11.99 (-0.66%)
MU   67.88 (+0.07%)
CGC   0.69 (+0.40%)
GE   107.52 (-0.22%)
DIS   79.69 (+0.19%)
AMC   7.97 (+1.53%)
PFE   34.06 (+0.47%)
PYPL   58.21 (+1.59%)
NFLX   376.06 (-0.18%)
S&P 500   4,240.27 (+0.26%)
DOW   32,992.06 (-0.03%)
QQQ   356.81 (+0.53%)
AAPL   172.20 (-0.12%)
MSFT   316.44 (+0.97%)
META   300.48 (-0.15%)
GOOGL   133.54 (+0.84%)
AMZN   126.27 (+1.24%)
TSLA   249.85 (+1.35%)
NVDA   436.99 (+0.42%)
NIO   8.56 (-0.58%)
BABA   84.54 (+0.00%)
AMD   100.76 (+0.68%)
T   14.70 (-0.54%)
F   11.99 (-0.66%)
MU   67.88 (+0.07%)
CGC   0.69 (+0.40%)
GE   107.52 (-0.22%)
DIS   79.69 (+0.19%)
AMC   7.97 (+1.53%)
PFE   34.06 (+0.47%)
PYPL   58.21 (+1.59%)
NFLX   376.06 (-0.18%)
S&P 500   4,240.27 (+0.26%)
DOW   32,992.06 (-0.03%)
QQQ   356.81 (+0.53%)
AAPL   172.20 (-0.12%)
MSFT   316.44 (+0.97%)
META   300.48 (-0.15%)
GOOGL   133.54 (+0.84%)
AMZN   126.27 (+1.24%)
TSLA   249.85 (+1.35%)
NVDA   436.99 (+0.42%)
NIO   8.56 (-0.58%)
BABA   84.54 (+0.00%)
AMD   100.76 (+0.68%)
T   14.70 (-0.54%)
F   11.99 (-0.66%)
MU   67.88 (+0.07%)
CGC   0.69 (+0.40%)
GE   107.52 (-0.22%)
DIS   79.69 (+0.19%)
AMC   7.97 (+1.53%)
PFE   34.06 (+0.47%)
PYPL   58.21 (+1.59%)
NFLX   376.06 (-0.18%)
S&P 500   4,240.27 (+0.26%)
DOW   32,992.06 (-0.03%)
QQQ   356.81 (+0.53%)
AAPL   172.20 (-0.12%)
MSFT   316.44 (+0.97%)
META   300.48 (-0.15%)
GOOGL   133.54 (+0.84%)
AMZN   126.27 (+1.24%)
TSLA   249.85 (+1.35%)
NVDA   436.99 (+0.42%)
NIO   8.56 (-0.58%)
BABA   84.54 (+0.00%)
AMD   100.76 (+0.68%)
T   14.70 (-0.54%)
F   11.99 (-0.66%)
MU   67.88 (+0.07%)
CGC   0.69 (+0.40%)
GE   107.52 (-0.22%)
DIS   79.69 (+0.19%)
AMC   7.97 (+1.53%)
PFE   34.06 (+0.47%)
PYPL   58.21 (+1.59%)
NFLX   376.06 (-0.18%)
NASDAQ:MESO

Mesoblast (MESO) Stock Forecast, Price & News

$1.20
+0.01 (+0.84%)
(As of 10/3/2023 ET)
Compare
Today's Range
$1.16
$1.25
50-Day Range
$1.19
$4.15
52-Week Range
$1.16
$5.12
Volume
61,369 shs
Average Volume
149,983 shs
Market Capitalization
$195.41 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.13

Mesoblast MarketRank™ Forecast

Analyst Rating
Hold
2.17 Rating Score
Upside/​Downside
493.8% Upside
$7.13 Price Target
Short Interest
Healthy
0.58% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.44 out of 5 stars

Medical Sector

286th out of 965 stocks

Biological Products, Except Diagnostic Industry

44th out of 157 stocks


MESO stock logo

About Mesoblast (NASDAQ:MESO) Stock

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic refractory inflammatory bowel disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia.

MESO Price History

MESO Stock News Headlines

The Strategic Gold Play You Haven't Heard About
Experts recommend adding gold to your portfolio, but in what form? Some savvy investors are now rejecting coins and mining stocks in favor of a unique gold investment alternative. It holds explosive growth potential similar to a junior gold stock -- but with less risk exposure.
Analyst Expectations for Mesoblast's Future
Mesoblast Limited (MESO) Q4 2023 Earnings Call Transcript
William Blair Reaffirms Their Hold Rating on Mesoblast (MESO)
Would Buffett Approve of This Growth Strategy?
Warren Buffett's approach has been to find and invest in undervalued businesses with strong potential for growth. Taking this approach to heart and applying it to a Trillion Dollar industry has proved itself in a big way...achieving an incredible 400+% growth during a down market.
Why Shares of Mesoblast Are Down Monday
Why Shares of Mesoblast Are Plunging Friday
MESO - Mesoblast Limited
Is no FDA news bad news for Mesoblast shares?
See More Headlines
Receive MESO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Mesoblast and its competitors with MarketBeat's FREE daily newsletter.

MESO Company Calendar

Last Earnings
8/30/2023
Today
10/03/2023
Next Earnings (Estimated)
11/28/2023
Fiscal Year End
6/30/2024

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:MESO
Previous Symbol
OTCMKTS:MBLTY
Employees
83
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$7.13
High Stock Price Forecast
$17.00
Low Stock Price Forecast
$1.50
Forecasted Upside/Downside
+493.8%
Consensus Rating
Hold
Rating Score (0-4)
2.17
Research Coverage
6 Analysts

Profitability

Net Income
$-81,890,000.00
Net Margins
-1,061.43%
Pretax Margin
-1,094.53%

Debt

Sales & Book Value

Annual Sales
$7.50 million
Book Value
$3.08 per share

Miscellaneous

Free Float
132,227,000
Market Cap
$195.41 million
Optionable
Optionable
Beta
3.32
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for October 2023. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Dr. Silviu Itescu FACP (Age 66)
    FACRA, FRACP, MBBS (Hons), Founder, CEO, MD, Chairman of Scientific Advisory Board & Exec. Director
    Comp: $726.28k
  • Dr. Eric A. Rose M.D. (Age 72)
    Chief Medical Officer & Exec. Director
    Comp: $614.91k
  • Mr. Andrew Chaponnel B.Com.
    Interim Chief Fin. Officer
  • Ms. Dagmar Rosa-Bjorkeson M.B.A. (Age 59)
    M.S., Chief Operating Officer
  • Mr. Peter T. Howard B.Sc. (Age 55)
    L.L.B., BSc, LLB (Hons), Gen. Counsel & Corp. Exec.
  • Mr. Roger D. Brown BA
    Head of Spinal Orthopedic Disorders
  • Mr. Michael Schuster M.B.A. (Age 46)
    MS, BSc, MBA, Head of Pharma Partnering
  • Ms. Geraldine Storton B.Sc.
    M.B.A., Bsc, MMS, MBA, Head of Regulatory Affairs & Quality Management
  • Mr. Justin Horst B.S.
    Head of Manufacturing
  • Ms. Niva Sivakumar B.Com.
    L.L.B., Joint Company Sec.













MESO Stock - Frequently Asked Questions

Should I buy or sell Mesoblast stock right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mesoblast in the last year. There are currently 1 sell rating, 3 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" MESO shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MESO, but not buy additional shares or sell existing shares.
View MESO analyst ratings
or view top-rated stocks.

What is Mesoblast's stock price forecast for 2023?

6 brokerages have issued 1-year target prices for Mesoblast's shares. Their MESO share price forecasts range from $1.50 to $17.00. On average, they expect the company's share price to reach $7.13 in the next year. This suggests a possible upside of 493.8% from the stock's current price.
View analysts price targets for MESO
or view top-rated stocks among Wall Street analysts.

How have MESO shares performed in 2023?

Mesoblast's stock was trading at $2.91 at the start of the year. Since then, MESO stock has decreased by 58.8% and is now trading at $1.20.
View the best growth stocks for 2023 here
.

Are investors shorting Mesoblast?

Mesoblast saw a decrease in short interest during the month of September. As of September 15th, there was short interest totaling 941,200 shares, a decrease of 15.2% from the August 31st total of 1,110,000 shares. Based on an average trading volume of 522,000 shares, the days-to-cover ratio is presently 1.8 days.
View Mesoblast's Short Interest
.

When is Mesoblast's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 28th 2023.
View our MESO earnings forecast
.

How were Mesoblast's earnings last quarter?

Mesoblast Limited (NASDAQ:MESO) released its quarterly earnings results on Wednesday, August, 30th. The company reported ($0.14) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.17) by $0.03. The business had revenue of $2.14 million for the quarter, compared to analyst estimates of $2 million. Mesoblast had a negative trailing twelve-month return on equity of 16.32% and a negative net margin of 1,061.43%.

What other stocks do shareholders of Mesoblast own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Mesoblast investors own include Sorrento Therapeutics (SRNE), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Exelixis (EXEL), CRISPR Therapeutics (CRSP), Novavax (NVAX), Micron Technology (MU), Vaxart (VXRT) and AbbVie (ABBV).

When did Mesoblast IPO?

(MESO) raised $69 million in an initial public offering on Friday, November 13th 2015. The company issued 5,700,000 shares at $12.10 per share. J.P. Morgan and Credit Suisse served as the underwriters for the IPO and Maxim Group and Ladenburg Thalmann were co-managers.

What is Mesoblast's stock symbol?

Mesoblast trades on the NASDAQ under the ticker symbol "MESO."

How do I buy shares of Mesoblast?

Shares of MESO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Mesoblast's stock price today?

One share of MESO stock can currently be purchased for approximately $1.20.

How much money does Mesoblast make?

Mesoblast (NASDAQ:MESO) has a market capitalization of $195.41 million and generates $7.50 million in revenue each year. The company earns $-81,890,000.00 in net income (profit) each year or ($0.56) on an earnings per share basis.

How can I contact Mesoblast?

Mesoblast's mailing address is LEVEL 38 55 COLLINS STREET, MELBOURNE C3, 3000. The official website for the company is www.mesoblast.com. The company can be reached via phone at (139) 639-6036, via email at schond.greenway@mesoblast.com, or via fax at 61-3-9639-6030.

This page (NASDAQ:MESO) was last updated on 10/4/2023 by MarketBeat.com Staff

My Account -